Top Markets
#1 Siren Siren +33.89%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.23%
#3 Ribbita by Virtuals Ribbita by Virtuals +18.40%
#4 Cysic Cysic +18.25%
#5 Wiki Cat Wiki Cat +18.11%
#6 Velvet Velvet +17.03%
#7 PulseChain PulseChain +16.92%
#8 Bitway Bitway +16.03%
#9 KUB Coin KUB Coin +15.80%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.63%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rank in Stocks #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Share Price
$0.39
Market Cap
$13.79M
Change (1 day)
-13.53%
Change (1 year)
-68.80%
Country
IL
Trade NeuroSense Therapeutics Ltd. (NRSN)

Category

Healthcare
P/E ratio for NeuroSense Therapeutics Ltd. (NRSN)
P/E ratio as of 2026 TTM: 0
According to NeuroSense Therapeutics Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for NeuroSense Therapeutics Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.